Clinical Trials in Boston

Showing 7781-7800 of 17,836 trials

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283

The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Group 1: metastatic or recurrent melanoma with documented BRAFV600 mutation (n=20 evaluable patients) Group 2: metastatic colorectal cancer (CRC), or advanced non-small cell lung cancer (NSCLC) with documented BRAFV600 mutation (n=14 evaluable patients) Group 3: advanced solid tumors with documented PI3K pathway alterations (PIK3CA mutation or PTEN loss) (n=14 evaluable patients)

NeoplasmsMelanomaColorectal Neoplasm+1 more

Asana BioSciences24 participantsStarted Oct 2016

Los Angeles, California, United States • Tampa, Florida, United States • Boston, Massachusetts, United States +2 more locations

TERMINATEDPhase 2< 1 mile

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02036476

This is an open-label, non-randomized, phase 2 study to assess the feasibility of using cabozantinib in recurrent/metastatic Merkel Cell Carcinoma patients that progressed after platinum-based therapy.

Merkel Cell CarcinomaSkin Cancer

Dana-Farber Cancer Institute8 participantsStarted Feb 2014

Boston, Massachusetts, United States • Boston, Massachusetts, United States

TERMINATEDPhase 1< 1 mile

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259

This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an effective treatment for amyloid light-chain amyloidosis or light chain deposition disease

Light Chain Deposition DiseasePrimary Systemic Amyloidosis

Barbara Ann Karmanos Cancer Institute18 participantsStarted Mar 2013

Denver, Colorado, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +2 more locations

Study of ASN003 in Subjects With Advanced Solid Tumors

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Find Trials by Condition in Boston

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

The T1D Exchange Registry

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Eye Movement Rehabilitation in Low Vision Patients

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Integrated Treatment for Smoking Cessation & Anxiety in People With HIV

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Subject Evaluation of a 1064nm Diode Laser/RF

Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia